Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab for CRS in COVID-19 Pneumonia
NCT04362813Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2020
- Primary completion
- Sep 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of canakinumab in cytokine release syndrome (CRS), COVID-19 pneumonia, sponsored by Novartis. Started Apr 2020; status: completed.
02
Drugs
canakinumab
03
Conditions
cytokine release syndrome (CRS)COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04362813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04362813.